Press Releases

Press Releases

September 16, 2021
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today
Additional Formats
August 17, 2021
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Aug. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology
Additional Formats
August 2, 2021
CytomX Therapeutics to Present at Upcoming August Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform,
Additional Formats
Displaying 1 - 10 of 24